[1] Polymeropoulos M H, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease[J]. Science,1997,276(5321):2045-2047. [2] Krüger R, Kuhn W, Müller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease[J]. Nat Genet,1998,18(2):106-108. [3] Baba M, Nakajo S, Tu P H, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies[J]. Am J Pathol,1998,152(4):879-884. [4] Uchihara T, Giasson B I. Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies[J]. Acta Neuropathol. 2015,[Epub ahead of print]. [5] Volpicelli-Daley L A, Luk K C, Lee V M. Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite-like aggregates[J]. Nat Protoc, 2014,9(9):2135-2146. [6] Kalia L V, Kalia S K. α-synuclein and Lewy pathology in Parkinson's disease[J]. Curr Opin Neurol, 2015,28(4):375-381. [7] Spillantini M G, Crowther R A, Jakes R, et al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies[J]. Proc Natl Acad Sci U S A, 1998,95(11):6469-6473. [8] Miklya I, Pencz N, Hafenscher F, et al. The role of alpha-synuclein in Parkinson's disease[J]. Neuropsychopharmacol Hung, 2014,16(2):77-84. [9] Mizuno H, Fujikake N, Wada K. α-synuclein transgenic drosophila as a model of Parkinson's disease and related synucleinopathies[J]. Parkinsons Dis, 2010,2011:212706. [10] Martin L J. Transgenic mice with human mutant genes causing Parkinson's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration[J]. Rev Neurosci, 2007,18(2):115-136. [11] Kim S, Park J M, Moon J, et al. Alpha-synuclein interferes with cAMP/PKA-dependent upregulation of dopamine β-hydroxylase and is associated with abnormal adaptive responses to immobilization stress[J]. Exp Neurol, 2014,252:63-74. [12] Caudle W M, Colebrooke R E, Emson P C, et al. Altered vesicular dopamine storage in Parkinson's disease: a premature demise[J]. Trends Neurosci, 2008,31(6):303-308. [13] Cao P, Yuan Y, Pehek E A, et al. Alpha-synuclein disrupted dopamine homeostasis leads to dopaminergic neuron degeneration in Caenorhabditis elegans[J]. PLoS One, 2010,5(2):e9312. [14] Kisos H, Ben-Gedalya T, Sharon R. The clathrin-dependent localization of dopamine transporter to surface membranes is affected by α-synuclein[J]. J Mol Neurosci, 2014,52(2):167-176. [15] Butler B, Saha K, Rana T, et al. Dopamine transporter activity is modulated by α-synuclein[J]. J Biol Chem, 2015,[Epub ahead of print]. [16] Park J, Lee S B, Lee S, et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin[J]. Nature, 2006,441(7097):1157-1161. [17] Yang Y, Gehrke S, Imai Y, et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin[J]. Proc Natl Acad Sci U S A, 2006,103(28):10793-10798. [18] Anichtchik O, Diekmann H, Fleming A, et al. Loss of PINK1 function affects development and results in neurodegeneration in zebrafish[J]. J Neurosci, 2008,28(33):8199-8207. [19] Sallinen V, Kolehmainen J, Priyadarshini M, et al. Dopaminergic cell damage and vulnerability to MPTP in Pink1 knockdown zebrafish[J]. Neurobiol Dis, 2010,40(1):93-101. [20] Gayrard C, Borghi N. FRET-based molecular tension microscopy[J]. Methods, 2015,[Epub ahead of print]. [21] Shrestha D, Jenei A, Nagy P, et al. Understanding FRET as a research tool for cellular studies[J]. Int J Mol Sci, 2015,16(4):6718-6756. [22] Tyagi S, Lemke E A. Single-molecule FRET and crosslinking studies in structural biology enabled by noncanonical amino acids[J]. Curr Opin Struct Biol, 2015,32:66-73. [23] Nouar R, Devred F, Breuzard G, et al. FRET and FRAP imaging: approaches to characterise tau and stathmin interactions with microtubules in cells[J]. Biol Cell, 2013,105(4):149-161. [24] Sipieter F, Vandame P, Spriet C, et al. From FRET imaging to practical methodology for kinase activity sensing in living cells[J]. Prog Mol Biol Transl Sci, 2013,113:145-216. [25] Li Y H, Gao N, Ye Y W, et al. Alpha-synuclein functions as a negative regulator for expression of tyrosine hydroxylase[J]. Acta Neurol Belg, 2011,111(2):130-135. [26] Tehranian R, Montoya S E, Van Laar A D, et al. Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells[J]. J Neurochem, 2006,99(4):1188-1196. [27] Liu W, Vives-Bauza C, Acín-Peréz- R, et al. PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease[J]. PLoS One, 2009,4(2):e4597. [28] Todd A M, Staveley B E. Pink1 suppresses alpha-synuclein-induced phenotypes in a Drosophila model of Parkinson's disease[J]. Genome, 2008,51(12):1040-1046. [29] Hoepken H H, Gispert S, Azizov M, et al. Parkinson patient fibroblasts show increased alpha-synuclein expression[J]. Exp Neurol, 2008,212(2):307-313. |